Subsequent treatment and outcomes
| . | Rd continuous . | Rd18 . | MPT . |
|---|---|---|---|
| All second-line treatment, n/n (%) | 299/535 (56) | 377/541 (70) | 381/547 (70) |
| CR, n (%) | 17 (6) | 23 (6) | 19 (5) |
| VGPR, n (%) | 41 (14) | 51 (14) | 50 (13) |
| PR or better, n (%) | 134 (45) | 196 (52) | 173 (45) |
| Median time from 2nd to 3rd line, mo | 16.6 | 18.9 | 14.1 |
| Bortezomib-based second-line treatment, n/n (%)* | 179/299 (60) | 208/377 (55) | 170/381 (45) |
| CR, n (%) | 11 (6) | 14 (7) | 7 (4) |
| VGPR, n (%) | 33 (18) | 33 (16) | 24 (14) |
| PR or better, n (%) | 96 (54) | 110 (53) | 74 (44) |
| Median time from 2nd to 3rd line, mo | 16.4 | 15.9 | 10.6 |
| Median OS, mo | 51.8 | 51.9 | 42.2 |
| Lenalidomide-based second-line treatment, n/n (%)† | 41/299 (14) | 82/377 (22) | 150/381 (39) |
| CR, n (%) | 4 (10) | 3 (4) | 10 (7) |
| VGPR, n (%) | 3 (7) | 14 (17) | 20 (13) |
| PR or better, n (%) | 15 (37) | 51 (62) | 77 (51) |
| Median time from 2nd to 3rd line, mo | 15.5 | 23.2 | 17.7 |
| Median OS, mo | NR | 80.1 | 62.6 |
| Thalidomide-based second-line treatment, n/n (%)‡ | 36/299 (12) | 30/377 (8) | 25/381 (7) |
| CR, n (%) | 2 (6) | 1 (3) | 0 |
| VGPR, n (%) | 3 (8) | 3 (10) | 3 (12) |
| PR or better, n (%) | 16 (44) | 12 (40) | 10 (40) |
| Median time from 2nd to 3rd line, mo | 19.6 | 16.5 | 14.9 |
| Median OS, mo | 52.9 | 62.3 | 46.2 |
| Other second-line treatment, n/n (%)§ | 41/299 (14) | 49/377 (13) | 33/381 (9) |
| CR, n (%) | 0 | 4 (8) | 1 (3) |
| VGPR, n (%) | 2 (5) | 1 (2) | 3 (9) |
| PR or better, n (%) | 6 (15) | 19 (39) | 11 (33) |
| Median time from 2nd to 3rd line, mo | 14.2 | 34.8 | 19.4 |
| Median OS, mo | 41.1 | 79.1 | 62.1 |
| . | Rd continuous . | Rd18 . | MPT . |
|---|---|---|---|
| All second-line treatment, n/n (%) | 299/535 (56) | 377/541 (70) | 381/547 (70) |
| CR, n (%) | 17 (6) | 23 (6) | 19 (5) |
| VGPR, n (%) | 41 (14) | 51 (14) | 50 (13) |
| PR or better, n (%) | 134 (45) | 196 (52) | 173 (45) |
| Median time from 2nd to 3rd line, mo | 16.6 | 18.9 | 14.1 |
| Bortezomib-based second-line treatment, n/n (%)* | 179/299 (60) | 208/377 (55) | 170/381 (45) |
| CR, n (%) | 11 (6) | 14 (7) | 7 (4) |
| VGPR, n (%) | 33 (18) | 33 (16) | 24 (14) |
| PR or better, n (%) | 96 (54) | 110 (53) | 74 (44) |
| Median time from 2nd to 3rd line, mo | 16.4 | 15.9 | 10.6 |
| Median OS, mo | 51.8 | 51.9 | 42.2 |
| Lenalidomide-based second-line treatment, n/n (%)† | 41/299 (14) | 82/377 (22) | 150/381 (39) |
| CR, n (%) | 4 (10) | 3 (4) | 10 (7) |
| VGPR, n (%) | 3 (7) | 14 (17) | 20 (13) |
| PR or better, n (%) | 15 (37) | 51 (62) | 77 (51) |
| Median time from 2nd to 3rd line, mo | 15.5 | 23.2 | 17.7 |
| Median OS, mo | NR | 80.1 | 62.6 |
| Thalidomide-based second-line treatment, n/n (%)‡ | 36/299 (12) | 30/377 (8) | 25/381 (7) |
| CR, n (%) | 2 (6) | 1 (3) | 0 |
| VGPR, n (%) | 3 (8) | 3 (10) | 3 (12) |
| PR or better, n (%) | 16 (44) | 12 (40) | 10 (40) |
| Median time from 2nd to 3rd line, mo | 19.6 | 16.5 | 14.9 |
| Median OS, mo | 52.9 | 62.3 | 46.2 |
| Other second-line treatment, n/n (%)§ | 41/299 (14) | 49/377 (13) | 33/381 (9) |
| CR, n (%) | 0 | 4 (8) | 1 (3) |
| VGPR, n (%) | 2 (5) | 1 (2) | 3 (9) |
| PR or better, n (%) | 6 (15) | 19 (39) | 11 (33) |
| Median time from 2nd to 3rd line, mo | 14.2 | 34.8 | 19.4 |
| Median OS, mo | 41.1 | 79.1 | 62.1 |
The most common second-line bortezomib-based regimens included bortezomib + dexamethasone (213 patients; 38%), bortezomib + melphalan + prednisone (110 patients; 20%), bortezomib + cyclophosphamide + dexamethasone (63 patients; 11%), bortezomib monotherapy (32 patients; 6%), and bendamustine + bortezomib + dexamethasone (26 patients; 5%).
The most common lenalidomide-based second-line regimens in the Rd continuous, Rd18, and MPT arms were Rd (24 [59%], 60 [73%], and 110 [73%] patients), lenalidomide monotherapy (13 [32%], 7 [9%], and 12 [8%]), Rd + investigational drug (1 [2%], 6 [7%], and 3 [2%]), Rd + monoclonal antibodies (0, 0, and 7 [5%]), and Rd + carfilzomib (0, 3 [4%], and 2 [1%]).
The most common thalidomide-based regimens included MPT (52 [57%]) and thalidomide monotherapy (14 [15%]).
The most common regimens in this category included melphalan + prednisone (41 [33%]) and dexamethasone monotherapy (18 [15%]); carfilzomib (as either carfilzomib + dexamethasone or carfilzomib + cyclophosphamide + dexamethasone) was given to 1 (2%), 6 (12%), and 2 (6%) patients in Rd continuous, Rd18, and MPT, respectively.
NR, not reached.